secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0000320017-24-000006
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Therapeutics reports FY2023 net loss $20.8M; cash $50.5M; ASCEND trial on track for Q4 2024 data
--------------------------------------------------------------------------------

- Net loss of $20.8M for FY2023 vs $54.2M in FY2022; operating expenses $25.7M (down 55% YoY).
- Cash, cash equivalents, and marketable securities of $50.5M; runway projected into early 2026.
- Phase 2b ASCEND trial in mPDAC fully enrolled; top-line data expected Q4 2024; complete data mid-2025.
- R&D expenses $12.7M vs $13.1M prior year; G&A expenses $13.0M vs $14.1M.
- Multiple Phase 2a trials ongoing (BOLSTER, CENDIFOX, iLSTA, GBM); Qilu licensee progressing in China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001724000006/0000320017-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001724000006/clbs-20240229.htm
  HTML page:      https://secwatch.observer/filing/0000320017-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer